Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1099

1.

Drug development for cancer chemoprevention: focus on molecular targets.

Johnson KA, Brown PH.

Semin Oncol. 2010 Aug;37(4):345-58. doi: 10.1053/j.seminoncol.2010.05.012. Review.

PMID:
20816505
2.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
3.

Cancer Drug Development: New Targets for Cancer Treatment.

Curt GA.

Oncologist. 1996;1(3):II-III.

PMID:
10387987
4.

Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.

Greenwald P.

J Cell Biochem Suppl. 1996;25:29-36. Review.

PMID:
9027595
5.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
6.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420
7.

The retinoids and cancer prevention mechanisms.

Dragnev KH, Rigas JR, Dmitrovsky E.

Oncologist. 2000;5(5):361-8. Review.

8.
9.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
10.
11.

Development of chemopreventive agents for lung and upper aerodigestive tract cancers.

Kelloff GJ, Boone CW, Steele VK, Perloff M, Crowell J, Doody LA.

J Cell Biochem Suppl. 1993;17F:2-17. Review.

PMID:
8412195
12.

Molecular targets for cancer chemoprevention.

William WN Jr, Heymach JV, Kim ES, Lippman SM.

Nat Rev Drug Discov. 2009 Mar;8(3):213-25. doi: 10.1038/nrd2663. Review.

PMID:
19247304
13.

Chemoprevention of colorectal cancer: ready for routine use?

Arber N, Levin B.

Curr Top Med Chem. 2005;5(5):517-25. Review.

PMID:
15974946
14.

Anticancer Drug Development: The Way Forward.

Connors T.

Oncologist. 1996;1(3):180-181.

15.
16.

Targeted therapy of metastatic breast cancer.

Sánchez-Muñoz A, Pérez-Ruiz E, Jiménez B, Ribelles N, Márquez A, García-Ríos I, Alba Conejo E.

Clin Transl Oncol. 2009 Oct;11(10):643-50. Review.

PMID:
19828406
17.

Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.

Lorusso PM, Eder JP.

Expert Opin Investig Drugs. 2008 Jul;17(7):1013-28. doi: 10.1517/13543784.17.7.1013 . Review.

PMID:
18549338
18.

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

Bellmunt J, Hussain M, Dinney CP.

Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S85-104. Review.

PMID:
12850530
19.

The curability of breast cancer and the treatment of advanced disease.

Guarneri V, Conte PF.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. Review.

PMID:
15107948
20.

Emerging targeted therapies for breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

J Clin Oncol. 2010 Jul 10;28(20):3366-79. doi: 10.1200/JCO.2009.25.4011. Review.

PMID:
20530283
Items per page

Supplemental Content

Support Center